This is the authors' abstract. We don't add key points for this paper.
Background: Asthma is a chronic respiratory condition marked by airway inflammation and fluctuating airflow obstruction. Biomarkers such as serum periostin and blood eosinophil count have been proposed to reflect type 2 airway inflammation and may correlate with disease severity. Objective: The current research attempted to evaluate the correlation between serum periostin concentrations and blood eosinophil counts with asthma severity among patients in Hillah City. Methods: Patients with asthma participated in a cross-sectional study categorized into mild, moderate, and severe classifications with respect to predicted FEV₁ percentages. Serum periostin levels (ng/mL) and absolute blood eosinophil counts (10³/μL) were measured. ANOVA and chi-square tests were applied to assess statistical associations between biomarker levels and asthma severity. Results: A significant increase in serum periostin levels was observed with increasing asthma severity (mean ± SD: mild 48.72 ± 6.51; moderate 54.36 ± 7.84; severe 60.91 ± 9.17 ng/mL; p < 0.001). Similarly, the prevalence of eosinophilia (>300 cells/μL) was significantly higher in severe asthmatics (p = 0.002). There is a moderately significant association observed between periostin levels and eosinophil counts (r = 0.42, p < 0.001). Conclusion: Serum periostin and eosinophil count are significantly associated with asthma severity, supporting their potential role as biomarkers for monitoring disease progression and guiding targeted therapies in Hillah City.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hamod et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: